IDT Australia is an innovative science and technology company providing expert pharmaceutical services globally.
For more than four decades years, the team at IDT has brought expertise and innovation to local and international pharmaceutical projects.
We specialise in high containment, high potency manufacture of API and finished dose products (including beta lactams), microbiological and analytical testing, clinical packaging, and pharmacy services.
From initial drug development to clinical trials, IDT is the partner of choice for pharmaceutical companies worldwide, including: Pfizer, Johnson & Johnson, Roche, Teva and Bayer.
From the time we receive your project request we work to better understand your needs and strive to uncover solutions that deliver improved costs, more effective outcomes and faster completion rates.
In 1965 Dean of the Victorian College of Pharmacy Nigel Manning and his colleagues conceived an idea - to establish an institute of industrial pharmacy. This ambition was included in the Victorian College of Pharmacy Campus’ development strategy in 1970 and was realised five years later.
On October 14 1975, the Institute of Drug Technology Limited (IDT) was established as an independent company, and as an academic-industrial interface operating in conjunction with the Victorian College of Pharmacy Limited (VCP).
Between 1975 and 1982, IDT established a reputation for providing high quality contract and consultancy services. It relied on academic staff from the VCP as consultants and employed a small cohort full- time scientists. At that time the principal aim of the company was to further the drug and allied industries in Australia.
In 1982 Dr Graeme Blackman, then a Senior Lecturer at the VCP, was appointed Chairman and Executive Director and Professor of Pharmaceutical Chemistry. Under his guidance the company continued to prosper and commenced a new phase of growth.
In May 1982 the company was transitioned from a private company, to an unlisted public company. Shortly after, IDT announced its acquisition of the Nicholas Kiwi Central Laboratories (NKCL). On February 12 1988 IDT was listed on the ASX, following the issue of approximately 24% of capital to public investors.
Today, the IDT business includes:
- Research and Development
- Active pharmaceutical ingredient (API) and finished dosage form manufacture, clinical and commercial
- Project Management
- Chemical Services
- Analytical Chemistry
- Pharmacy Services
- Pharmaceutical development in all dosage forms
- Clinical packaging for early phase clinical trials
- Regulatory Affairs Services
Contact our team today to discuss your unique project requirements.